Cataract – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Cataract – Pipeline Review, H2 2016’, provides an overview of the Cataract pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cataract, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cataract and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Cataract

The report reviews pipeline therapeutics for Cataract by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Cataract therapeutics and enlists all their major and minor projects

The report assesses Cataract therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Cataract

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Cataract

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cataract pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

EyeGate Pharmaceuticals, Inc.

Genisphere LLC

Omeros Corporation

Plex Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Cataract Overview 6

Therapeutics Development 7

Pipeline Products for Cataract - Overview 7

Pipeline Products for Cataract - Comparative Analysis 8

Cataract - Therapeutics under Development by Companies 9

Cataract - Therapeutics under Investigation by Universities/Institutes 10

Cataract - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Cataract - Products under Development by Companies 13

Cataract - Products under Investigation by Universities/Institutes 14

Cataract - Companies Involved in Therapeutics Development 15

EyeGate Pharmaceuticals, Inc. 15

Genisphere LLC 16

Omeros Corporation 17

Plex Pharmaceuticals, Inc. 18

Cataract - Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

dexamethasone acetate - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

GL-249 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

lanosterol - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Small Molecule for Non-Surgical Cataracts and Multiple Sclerosis - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Small Molecule to Antagonize GPR161 for Central Nervous System Disorders, Oncology and Ophthalmology - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Small Molecule to Inhibit NFkB for Ophthalmology, Oncology and Immunology - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Small Molecules for Ophthalmology and CNS Disorders - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

VP-1001 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Cataract - Dormant Projects 39

Cataract - Discontinued Products 40

Cataract - Product Development Milestones 41

Featured News & Press Releases 41

Sep 07, 2016: Plex Pharmaceuticals awarded $299,173 NIH Phase I SBIR grant funding to find non-surgical treatments for Cataracts 41

Appendix 42

Methodology 42

Coverage 42

Secondary Research 42

Primary Research 42

Expert Panel Validation 42

Contact Us 42

Disclaimer 43

List of Tables

List of Tables

Number of Products under Development for Cataract, H2 2016 7

Number of Products under Development for Cataract – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Cataract – Pipeline by EyeGate Pharmaceuticals, Inc., H2 2016 15

Cataract – Pipeline by Genisphere LLC, H2 2016 16

Cataract – Pipeline by Omeros Corporation, H2 2016 17

Cataract – Pipeline by Plex Pharmaceuticals, Inc., H2 2016 18

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Stage and Target, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 23

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 27

Cataract – Dormant Projects, H2 2016 39

Cataract – Discontinued Products, H2 2016 40

List of Figures

List of Figures

Number of Products under Development for Cataract, H2 2016 7

Number of Products under Development for Cataract – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Targets, H2 2016 20

Number of Products by Stage and Targets, H2 2016 20

Number of Products by Mechanism of Actions, H2 2016 22

Number of Products by Stage and Mechanism of Actions, H2 2016 22

Number of Products by Routes of Administration, H2 2016 24

Number of Products by Stage and Routes of Administration, H2 2016 24

Number of Products by Molecule Types, H2 2016 26

Number of Products by Stage and Molecule Types, H2 2016 26

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports